Akebia Therapeutics (AKBA) Misses Q1 EPS by 6c

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $61.7 million versus the consensus estimate of $44.22 million.

GUIDANCE:

Akebia Therapeutics sees FY2022 revenue of $165-170 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lands' End (LE) Tops Q1 EPS by 8c ; Offers Guidance
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance